C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis: These phase 2 studies suggest that avacopan is well tolerated and that specific inhibition of the C5a/C5aR interaction on inflammatory cells may improve outcomes in ANCA-associated vasculitis, while reducing glucocorticoid exposure and their associated side effects observed with the standard of care.